Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Common Equity (2020 - 2026)

PROCEPT BioRobotics has reported Common Equity over the past 7 years, most recently at $347.7 million for Q1 2026.

  • Quarterly Common Equity fell 10.66% to $347.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $347.7 million through Mar 2026, down 10.66% year-over-year, with the annual reading at $365.9 million for FY2025, 9.04% down from the prior year.
  • Common Equity was $347.7 million for Q1 2026 at PROCEPT BioRobotics, down from $365.9 million in the prior quarter.
  • Over five years, Common Equity peaked at $402.2 million in Q4 2024 and troughed at $155.9 million in Q2 2023.
  • The 5-year median for Common Equity is $264.0 million (2024), against an average of $285.1 million.
  • Year-over-year, Common Equity surged 230.38% in 2022 and then plummeted 34.82% in 2023.
  • A 5-year view of Common Equity shows it stood at $197.1 million in 2022, then surged by 42.46% to $280.8 million in 2023, then soared by 43.27% to $402.2 million in 2024, then decreased by 9.04% to $365.9 million in 2025, then fell by 4.98% to $347.7 million in 2026.
  • Per Business Quant, the three most recent readings for PRCT's Common Equity are $347.7 million (Q1 2026), $365.9 million (Q4 2025), and $380.3 million (Q3 2025).